CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570)
BioMarin (NASDAQ: BMRN) develops and commercializes biopharmaceuticals for serious diseases and medical conditions, focusing on product candidates that address currently unmet medical needs; suggest a clear-cut development profile; and provide an opp...Show all
Company (Alive / Active)
Phone: 415-506-6700
770 Lindaro St.
San Rafael, 94901
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| BioMarin Pharmaceutical | $66M | May 7, 2001 |
| See all 16 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|---|---|---|
| BankInvest Group | Venture Capital | Denmark | Unattributed VC - II |
| Franklin Templeton Investments | Asset/Investment Management | Toronto, Ontario, Canada | Unattributed VC - III |
| BayStar Capital | Venture Capital | Larkspur, California, United States | Unattributed VC - III |
| Equity4Life | Unattributed VC - III | ||
| Glyko Biomedical | Unattributed VC - II, Unattributed VC |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Processes of synthesizing dihydropyridophthalazinone derivatives | Jun 02, 2014 | Mar 27, 2018 | Patent |
| Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (mps) vi and iva | Apr 12, 2016 | Mar 13, 2018 | Patent |
| Histone deacetylase inhibitors | Oct 28, 2016 | Mar 06, 2018 | Patent |
| Use of c-type natriuretic peptide variants to treat skeletal dysplasia | Aug 01, 2016 | Mar 06, 2018 | Patent |
| Variants of c-type natriuretic peptide | Jan 23, 2015 | Feb 13, 2018 | Patent |
